

M. PÉREZ<sup>1</sup>, M. MERCHANTE<sup>1</sup>, L. CAZORLA<sup>1</sup>, A. MAGALLÓN<sup>1</sup>, A. PINILLA<sup>1</sup>, J. PERALES<sup>1</sup>, A. LÓPEZ<sup>1</sup>, R. ABAD<sup>1</sup>, J. BUENO-NOTIVOL<sup>2</sup>.

<sup>1</sup>UNIVERSITARY HOSPITAL MIGUEL SERVET, HOSPITAL PHARMACY, ZARAGOZA, SPAIN.

<sup>2</sup>UNIVERSITARY HOSPITAL MIGUEL SERVET, PSYCHIATRY, ZARAGOZA, SPAIN.

## BACKGROUND AND IMPORTANCE

- Efficacy** and **toxicity** are strictly related with Vancomycin serum concentrations.
- Special care must be considered when treating **paediatric** patients with this antibiotic.

## AIM AND OBJECTIVES


- 1 - Analysis of the **compliance to the Vancomycin dosage protocol** in paediatrics of a third level hospital.
- 2.-Evaluation of the **impact of pharmacokinetic monitoring** on the adequacy of therapeutic levels.



## MATERIAL AND METHODS

Descriptive, observational and retrospective study

2017



2020

From the beginning of the implementation of the vancomycin monitoring programme (January 2017) until August 2020

It included all paediatric patients who have received recommendations for dosage adjustment after determination of vancomycin serum levels.



Demographic variables:



- Gender
- Age/prematurity
- Prescribing services



Clinical variables



- Diagnostic
- Initial dose
- Initial and post-recommendation vancomycin serum levels

The adherence to the initial dosage to the protocol, the serum levels at the beginning of the monitoring programme and serum levels at the end of treatment were studied.

## RESULTS



## CONCLUSIONS AND RELEVANCE

The variability in the paediatric patients of this study shows that, even though most prescriptions are in accordance with the protocol, only 30.8% achieve therapeutic levels. This percentage doubled after the monitoring programme, which highlights the great value of monitoring and personalised dose recommendations, especially recommended in this type of patient.

